Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 22;13(6):370.
doi: 10.3390/toxins13060370.

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

Dirk Dressler  1 , Lizhen Pan  2   3 , Junhui Su  2   3 , Fei Teng  2   3 , Lingjing Jin  2   4
Affiliations
Review

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

Dirk Dressler et al. Toxins (Basel). .

Abstract

In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North America.

Keywords: Chinese botulinum toxin; botulinum toxin; complete English bibliography; formalised review; lanbotulinumtoxinA; therapy.

PubMed Disclaimer

Conflict of interest statement

Dirk Dressler DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. He provides professional consulting services to pharmaceutical companies and professional investment institutions on all aspects of botulinum toxin drugs.

References

    1. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus. 1980;17:21–25. doi: 10.3928/0191-3913-19800101-06. - DOI - PubMed
    1. Dressler D. Botulinum toxin drugs: Brief history and outlook. J. Neural Transm. 2016;123:277–279. doi: 10.1007/s00702-015-1478-1. - DOI - PubMed
    1. Barbosa P.M., Rodrigues G.R., de Oliveira D.S., de Souza C.P., Tumas V. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. Clin. Neuropharmacol. 2015;38:221–226. doi: 10.1097/WNF.0000000000000107. - DOI - PubMed
    1. Dressler D., Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev. Neurother. 2017;17:487–494. doi: 10.1080/14737175.2017.1262258. - DOI - PubMed
    1. He X., Miao C.H., Li X.J., Wang Y.T., Liang Q., Zhang X.P., Wang Y.C. Biological characteristics and quality of botulinum toxin type A for injection. Chin. J. Biol. 2012;25:1488–1491. doi: 10.1124/pr.116.012658. (In Chinese) - DOI

Publication types

Substances